What is VYXEOS?
VYXEOS (vix-e-ose) is an intravenous (IV) chemotherapy used for the treatment of adults and pediatric patients 1 year and older with certain types of newly-diagnosed secondary acute myeloid leukemia (sAML): therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
How is VYXEOS different?
VYXEOS is an advancement from traditional chemotherapy for adults with certain types of newly-diagnosed sAML. It is the only treatment for these types of AML that combines 2 currently used, effective chemotherapies into tiny, bubble-like carriers called liposomes, which carry the drugs to the bone marrow. The liposomes are taken up by leukemia cells (blasts) to a greater extent than by normal cells. Once inside, the liposomes release the drugs to help kill the blasts. This type of technology, combining 2 drugs within a liposome, is the first of its kind in AML treatment.
Chemotherapy solutions can be various colors. The VYXEOS solution is purple.